884504-76-1

Basic information

• Product Name: 4-(chloromethyl)-2-(3-fluorophenyl)-5-methyl-1,3-oxazole(SALTDATA: FREE)
• Synonyms: 4-(chloromethyl)-2-(3-fluorophenyl)-5-methyl-1,3-oxazole(SALTDATA: FREE);4-(chloromethyl)-2-(3-fluorophenyl)-5-methyl-1,3-oxazole
• CAS NO: 884504-76-1
• Molecular Formula: C₁₁H₉ClFNO
• Molecular Weight: 225.6466632
• Mol File: 884504-76-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(chloromethyl)-2-(3-fluorophenyl)-5-methyl-1,3-oxazole(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(chloromethyl)-2-(3-fluorophenyl)-5-methyl-1,3-oxazole(SALTDATA: FREE)(884504-76-1)
• EPA Substance Registry System: 4-(chloromethyl)-2-(3-fluorophenyl)-5-methyl-1,3-oxazole(SALTDATA: FREE)(884504-76-1)

Safety Data

• Hazardous Substances Data: 884504-76-1(Hazardous Substances Data)

Upstream product

• 456-48-4 3-Fluorobenzaldehyde 
• 932779-61-8 2-(3-fluorophenyl)-4,5-dimethyl-oxazole 3-oxide 
• 932727-10-1 4,5-dimethyl-2-(3-fluorophenyl)oxazol 3-oxide hydrochloride 

Downstream Products

• 1593269-78-3 2-(4-{[{[2-(3-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]-methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoic acid 
• 1593269-65-8 tert-butyl 2-(4-{[{[2-(3-fluorophenyl)-5-methyl-1,3-oxazol-4-yl] methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoate 

Relevant articles and documents

Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties

We describe herein the design, syntheses and structure-activity relationships (SAR) of novel zwitter-ionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. In the previous report, we obtained compound 1 showing potent PPARα/γ dual agonistic activities, together with a great glucose lowering effect in the db/db mice. However, this compound possessed fatal issues such as potent cytochrome P450 (CYP)3A4 direct inhibitory activity. Thus, we carried out the medicinal optimization to improve these while maintaining the potent PPAR agonistic activity. As a result, the issues were addressed by changing the furan ring to a low lipophilic 1,3,4-oxadiazole ring. Additionally, these oxadiazole derivatives exhibited a significant decrease in plasma glucose and plasma triglyceride levels without marked weight gain.

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

PHENOXYACETIC ACID DERIVATIVES AND DRUGS USING THE SAME

It is intended to provide a novel compound having an excellent agonism to PPARs α/γ and desirable properties as a drug. An agonist to peroxisome proliferator-activated receptors α/γ which is represented by the general formula (I) (wherein Q represents an optionally substituted benzene ring or pyridine ring; R1 and R2 represent each an optionally substituted phenyl group or a 5- to 6-membered aromatic heterocycle group; X, Y and Z independently represent each C, O, S or N; R3 to R9 represent each a hydrogen atom, a lower alkyl group, etc.; and n is an integer of from 0 to 3.